GLP-1 Medications and Vision Loss: The FDA NAION Warning Explained
On November 9, 2026, the FDA announced that all GLP-1 medications must carry a warning about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision loss in one eye. The risk is rare. Do not stop your medication on your own, and call your doctor right away if you notice a sudden change in your vision.
If you take Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 medication, here is what the FDA’s new warning says, how rare the problem is, and which symptoms mean you should call right away.
What the FDA Announced
On November 9, 2026, the U.S. Food and Drug Administration issued a Drug Safety Communication about GLP-1 receptor agonists, the family of medications used for type 2 diabetes and weight management. After reviewing clinical trials, insurance-claims data and published studies, the FDA concluded there is a potential increased risk of a rare eye condition called NAION in people taking these medications.
The FDA is requiring every manufacturer to add this information to the Warnings and Precautions section of the drug’s label. The FDA did not tell patients to stop taking these medications.
Which Medications Are Covered?
The warning applies to the whole class, whether the medication is prescribed for diabetes, weight, or another approved use:
- Semaglutide: Ozempic, Wegovy, Rybelsus
- Tirzepatide: Mounjaro, Zepbound
- Dulaglutide: Trulicity
- Liraglutide: Victoza, Saxenda, and Xultophy (liraglutide with insulin degludec)
- Lixisenatide with insulin glargine: Soliqua
- Exenatide (generic)
- Orforglipron: Foundayo
The FDA noted that NAION cases have been reported with every GLP-1 medication currently on the market.
What Is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front of the optic nerve, the nerve that carries signals from the eye to the brain, is reduced. The result is sudden, painless loss of vision in one eye. The vision loss can be permanent.
NAION is a problem of the optic nerve. It is a different condition from diabetic retinopathy, which affects the retina, so your regular diabetic eye exams remain just as important as before.
How Big Is the Risk?
NAION is rare, with or without a GLP-1 medication. The FDA’s numbers give a sense of scale:
- Clinical trials: across 126 trials with more than 134,000 patients, there were 15 probable NAION cases: 10 among people taking a GLP-1 medication and 5 among people taking placebo. That works out to about 6.4 cases per 100,000 person-years with GLP-1 medications versus about 3.8 per 100,000 person-years in the comparison groups.
- Adults with type 2 diabetes in insurance data (2019–2024): NAION occurred at roughly 26 to 32 cases per 100,000 person-years. The rate with GLP-1 medications was higher than with DPP-4 inhibitors. Compared with SGLT-2 inhibitors, the difference was not statistically significant.
- General population: published rates of NAION in adults over 50 range from about 2.3 to 10.2 cases per 100,000 people per year.
The FDA also reported that animal studies did not identify a way that GLP-1 medications would cause NAION. That is one reason the agency describes the risk as “potential.”
Symptoms to Watch For
Contact your doctor right away if you notice any of the following, especially in one eye:
- Sudden, painless loss of vision, often noticed when you wake up
- Blind spots or tunnel vision
- Blurry or hazy areas, including in the center of your vision
- Colors that look distorted
If NAION is suspected, the FDA advises prompt referral to an ophthalmologist. If you cannot reach our office or your eye doctor, get urgent medical care.
Who Is at Higher Risk?
The cause of NAION is not fully understood. The FDA lists these risk factors:
- Smoking
- Diabetes
- High blood pressure
- Sleep apnea
- Anemia
- Kidney disease
If you have had NAION in one eye, your other eye is at increased risk. Please tell us if you have ever been diagnosed with NAION, so we can talk through whether a GLP-1 medication is right for you.
What You Should Do
- Keep taking your medication unless your doctor tells you otherwise. Do not stop on your own.
- Know the symptoms listed above, and call right away if you notice them.
- Tell us about your eye history, especially any past NAION or unexplained vision loss.
- Keep up with regular eye exams, especially if you have diabetes.
- Bring your questions to your next visit, or call us at 832-968-7003.
You can also report a side effect directly to the FDA through its MedWatch program, online or by calling 1-800-332-1088.
Common Questions
Can GLP-1 medications cause vision loss?
The FDA has concluded there is a potential increased risk of a rare eye condition called NAION (non-arteritic anterior ischemic optic neuropathy) in people taking GLP-1 medications. NAION can cause sudden, painless vision loss in one eye, and the loss may be permanent. It is rare: in the FDA's review of 126 clinical trials there were about 6.4 cases per 100,000 person-years with GLP-1 medications, compared with about 3.8 in comparison groups.
Which medications does the FDA warning cover?
The warning covers every GLP-1 receptor agonist: Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), Xultophy, Soliqua, exenatide and Foundayo (orforglipron).
Should I stop taking my GLP-1 medication?
Do not stop on your own. The FDA has not told patients to stop these medications. It advises people who have had NAION to talk with their health care professional about whether to continue. If you are worried about your own risk, call our office so we can review it with you.
What symptoms should I watch for?
Sudden, painless loss of vision in one eye, often noticed on waking; blind spots or tunnel vision; blurry or hazy areas, including in the center of your vision; and colors that look distorted. Contact your doctor right away if you notice any of these.
Who is at higher risk of NAION?
According to the FDA, risk factors for NAION include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. If you have had NAION in one eye, the other eye is at increased risk.
Source
Our endocrinology team can review your personal risk factors and help you decide what is right for you. Talk to Our Team
Our Team Prescribes GLP-1 Medications
Our providers are experienced with GLP-1 therapy for weight loss and diabetes. Book with any member of our team:
Book an Appointment → or call 832-968-7003